Decade in review—targeted therapy: Successes, toxicities and challenges in solid tumours

The rise of targeted therapy for solid tumours over the past decade has yielded a cornucopia of novel agents across an array of cancers. Amidst multiple acclaimed successes, targeted therapies are associated with considerable toxicity, and durable responses are often thwarted by genomic chaos driving the evolution of resistant clones; key examples of successes in solid tumours are highlighted herein.